Skip to main content

CCTG Connection



Published:
Category: Group updates
CCTG is looking for two Health Equity Leads
CCTG is seeking interested individuals with a background in health equity to serve as Health Equity Leads. Please submit the application form with a CV by May 30, 2025. Read More

Published:
Category: Group updates
CCTG at 2025 ASCO Annual Meeting

The ASCO 2025 Annual Meeting, is fast approaching and will be held from May 30 to June 3 in Chicago, Illinois -- This year the theme is of "Driving Knowledge to Action: Building a Better Future". This meeting will feature many CCTG trials and research so please see the list below to ensure you do not miss the oral presentations or poster presentations, showcasing the latest in CCTG research and clinical trial results.

 

Read More

Published:
Category: Group updates
2026 CCTG Annual Spring Meeting of Participants
Don't forget to mark your calendars and save the date for the next CCTG Spring Meeting which will be Friday, April 24 – Sunday, April 26, 2026 at the Chelsea Hotel in Toronto. Read More

Published:
Category: News
Call for Applications: Fall 2025 CIHR-ICR Early Career Researcher Workshop

The CIHR Early Career Researcher Workshop

As part of the CIHR commitment to promote capacity building in the Canadian cancer research landscape, the CIHR Institute of Cancer Research (CIHR-ICR), in partnership with the Canadian Cancer Research Alliance (CCRA), Canadian Cancer Society (CCS), Cancer Research Society (CRS), Ontario Institute for Cancer Research (OICR), and Terry Fox Research Institute (TFRI), has announced the open call for applications for its Early Career Researcher (ECR) Workshop.

Read More

Published:
Category: News
The Pharmacy Network Volunteer Positions
The CCTG Pharmacy Network is actively seeking pharmacy representation for the following:
  • Pharmacy Network Steering Group - 2nd Western Representative
  • Pharmacy Network Steering Group - Pharmacy Technician

The Steering Group is responsible for providing leadership for the Pharmacy Network.

Read More

Published:
Category: Publications
Publications: General Review
Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis
 
Immune checkpoint inhibitors (ICI) have become an important treatment option for cancer patients and has been associated with improved survival outcomes across various tumor types. Cannabinoids are active components of cannabis and include tetrahydrocannabinol (THC) and cannabidiol (CBD). Cannabis use has increased in Canadian cancer patients and is often used for symptom management.
Read More

Published:
Category: Trials
Trial closure: IND232

IND.232, a Phase II Study of Durvalumab (MEDI4736) with or without tremelimumab in patients with metastatic castration resistant prostate cancer, has permanently closed.

Read More

Published:
Category: Trials
Closed to accrual: MAC27

MAC27 - COMPASSHER2 residual disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and Tucatinib has closed to accrual.

Read More